Answers are grounded in this paper and cite their sources.
Sreeja Namilakonda, Sindhu Priya Botta,and Jannu Nikshiptha Dabigatran is a non-vitamin K antagonist oral anticoagulant (NOAC) whose widespread use for various indications has increased. Intracranial bleed in patients receiving dabigatran is a rare occurrence but can be fatal if reversible agent Idarucizumab is not administered immediately to reverse its effects.
No takes yet. Share an insight, caveat, or question.
A 2023 study studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: